ABSTRACT
4
extensive SEER-Medicare data to describe the changes of hazard on recurrence timing for women with breast cancer in the U.S. population. In the current study, we used SEER-Medicare data to identify recurrences over a 10 year period for women diagnosed with breast cancer between 1991 and 1997. We included only those women with American Joint Committee on Cancer (AJCC) stage I, II, or III invasive breast cancer identified in SEER data, and we then generated a hazard function of incidence of the first recurrence events considering the major prognostic factors over 10 years.
MATERIALS AND METHODS

Patients
We used the SEER-Medicare linked database for this study. The SEER program, supported by the U. S. National Cancer Institute (NCI), collects data from tumor registries; during the years included in this study, the database covered 14% to 25% of the U.S. population. Entitlement and Diagnosis Summary File (PEDSF). Patient treatment information regarding surgery, radiation, and chemotherapy were extracted from Medicare claims files for durable medical equipment (DME), physician (NCH), inpatient service (MEDPAR), and outpatient service files (OUTPAT). The study was reviewed and approved by the Institutional Review Board.
Identifying first recurrence events of breast cancer
To define recurrence, we modified the method by Earle et al. (20) . We excluded women with a second primary cancer, including breast cancer, within 10 years after primary breast cancer diagnosis. We also excluded those women who died within 6 months after the primary diagnosis. In most circumstances, women with recurrent breast cancer receive treatment without delay, suggesting that initiation of new treatment likely corresponds to the time of recurrence.
We defined a woman who had received chemotherapy, radiation, or surgery according to Medicare claim whenever there was a claim for chemotherapy administration, radiation, or surgery performed in any of three Medicare claims categories from outpatient setting, inpatient setting, or physician file. Surgical treatments for breast cancer were defined as patients who received breast-conserving surgery or Mastectomy. If a woman initially received breastconserving surgery, but involved mastectomy within timeframe, the woman was classified in the mastectomy group. The initial primary treatment was defined as having selected claim codes 1 month before or within 4 months after the date of diagnosis in SEER. Treatment for the first recurrence was defined as a claim for chemotherapy administration, radiation, or surgery 3 months or more after the end of initial primary treatment without encountering therapeutic chemotherapy, radiotherapy, or surgery. We were not able to evaluate treatment with hormonal therapy, since oral treatments were not included in the Medicare database over this time period, or patients who did not undergo treatment for metastases. All claim codes for defining treatment regimens are available within the attached appendix. Disease-free time interval between primary treatment and recurrent treatment was defined as after the end of the original treatment episode, identified as a three-month period with no documented delivery of therapeutic chemotherapy, radiotherapy, or surgery. We included only those women who were fully covered by Medicare Parts A and B during the follow-up periods and excluded those covered by HMO since their claims would not be complete.
The AJCC stages in the SEER data were used to categorize tumor stages in this study.
The hormone receptor-positive status was considered as mixed estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+) , i.e., ER+/no PR data, ER+/PR+, ER+/PR-, or ER-/PR+, or no ER data/PR+. The percentages of available ER, PR, and Hormone receptor status among the women were 80.8%, 78.3%, and 81.4%, respectively. Tumor histological grades were 
Data analysis
We used the hazard rate (HR) to characterize the first recurrence dynamics (21) . The annual HR of the first recurrence was defined as the conditional probability of recurrence in a time interval given that the women were free of recurrence at the beginning of the interval.
We estimated the HR by using Proc Lifetest in SAS through the Kaplan-Meier method, a nonparametric method that efficiently describes the data when no suitable theoretical distributions are known. For the graphical display of recurrence events, annual HRs were estimated using an Epanechnikov Kernel-like smoothing procedure for the purposes of better graphical display (22) . We also compared HRs stratified by such potential prognostic factors as breast cancer were estimated using the cumulative incidence method for competing risks (27, 28) . The competing event for these endpoints is breast cancer specific death prior to clinical evidence of recurrence, i.e., a patient who died prior to breast cancer recurrence was counted as failing from a competing cause at the time of death.
All statistical analyses were performed using SAS software (version 9.2, SAS, Chapel Hill, NC).
RESULTS
Patient characteristics
The study included 24,815 women, age 65 through 80 years old and diagnosed with primary breast cancer (AJCC stage I, II, or III) between 1991 and 1997. All their records were linked with Medicare enrollment records, and patients were fully covered by Medicare Plan A and B during the follow-up. We excluded women if they had developed a second primary breast cancer (n = 1,853) or other second primary cancers (n = 2,679) within 10 years after primary breast cancer diagnosis. We also excluded women who survived less than 6 months after primary breast cancer diagnosis (256). The final number of women included in the analysis was 20,027, and Table 1 
Hazard rate by age group
We categorized age at diagnosis as 65-69, 70-74, and 75-79 years old and analyzed the HR by stratifying age groups (Figure 2 ). Although the results suggested that younger women had a greater hazard of recurrence (P < 0.01), these findings did not show an obvious effect on the hazard rate on curves compared with the effect of tumor stages and therefore were not included in the further stratified analysis. 
However, it should be noted that the pathological specimen may not always capture the dominant component of the tumor grade within entire tumor lesion. Therefore, the category of tumor with unknown grade might also consist of a mixture of grades such as well-to-moderately differentiated or poorly differentiated histopathology within the same tumor.
Cumulative incidence from competing analysis
When treating breast cancer-specific death before evidence of recurrence as a competing risk, the 10 year estimated cumulative incidence of recurrence is 35% (95% CI, 0.34-0.36), 44% (95% CI, 0.43-0.45), and 56% (95% CI, 0.54-0.59) for the stage I, II, and III, respectively. On the other hand, when treating recurrence as a competing risk, the 10 year estimated cumulative incidence of death before recurrence is 0.9% (95% CI, 0.007-0.011), 4.7% (95% CI, 0.04-0.05), and 14% (95% CI, 0.12-0.16) for the stage I, II, and III, respectively.
The results of cumulative incidence from two competing events, i.e., recurrence and cancer-specific death before evidence of recurrence demonstrate that the hazard of competing risks of death was comparatively low, suggesting a relatively small competing risk. With a low competing risk of death, for the purpose of simplicity, the Kaplan-Meier analysis is sufficient.
Multivariate analysis of prognostic factors associated with development of recurrence
In Table 2 , multivariable Cox proportional hazard regression showed that the increased risk of recurrence of breast cancer was associated with advanced disease stage, moderate and poorly differently grades, and negative hormone receptor status (all P < 0.01). Women with stage III disease had a 2-fold greater risk than stage I women for developing recurrence (Hazard ratio, 2.04; 95% CI, 1.88 to 2.22). Older age was associated with lower risk of recurrence (all P < 0.01). The baseline Charlson comorbidity index score was not associated with the risk of recurrence (all P < 0.01). When both recurrent events and breast cancer-specific deaths prior to evidence of recurrence were treated as outcomes of interest, the results from Cox regression were nearly identical for all covariates compared with the first regression model (Table 2) .
DISCUSSION
Our study explored the extensive SEER-Medicare data to characterize how the hazard of the first recurrence of breast cancer among women varied with prognostic factors over 10 years.
The curves of hazards estimated from our study provide a rich view of the recurrence experience of women after primary treatment. Our results suggest that the greatest frequency of first recurrence occurred between 0 and 5 years of follow-up. We also found that most differences among prognostic factors for the first recurrence also occurred within this time period. Beyond 5 years, the hazards of recurrence were relatively constant within subtypes of patients. Women with poor prognostic features such as having advanced AJCC stage, hormone receptor -negative status, or poorly differentiated histological tumor grade were more likely to have more recurrence. Our study population consists of older postmenopausal women with breast cancers, and therefore, these findings might not necessarily apply to premenopausal women with breast cancers. The significant differences in hazard of the first recurrence occurred between 0 and 5 years after initial treatment; after year 5, the differences in hazards for all women were small. The observed variations in the risk of recurrence such as for timing and magnitude might differ depending on potential prognostic factors that were not included in this study. In this study, we sought to determine whether HRs of first recurrence among women with breast cancer differed and to provide evidence for developing strategies for follow-up schedules. This is the first use of the extensive SEER-Medicare data to describe the changes of hazard on recurrence timing for women with breast cancer, and the results from this study are comparable with the results of early studies from different patient populations (11) (12) (13) (14) (15) (16) (17) (18) (19) .
We did not observe evidence for a secondary peak in the distribution of hazard curves in our patient population, as reported in earlier studies (14, 29) . Earlier studies included women We observed that women with positive hormone receptor status had a lower risk of hazard of first recurrence in the first 5 years compared with women with negative hormone receptor status (P < 0.01). However, these data must be interpreted with caution, since women with hormone receptor positive disease would have been likely to be initially treated with hormonal therapy, which would not be captured in this study. Recurrence for patients with hormone receptor positive disease would not be captured until therapy with chemotherapy, on October 14, 2017. © 2012 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from radiation therapy, or surgery was initiated, which could be some time after the initial diagnosis of recurrence or never. Women with negative hormone receptor status had an increased risk of recurrence during the first 5 years, suggesting that more frequent follow-up visits may be needed for such women.
Although our results suggest that younger women have a greater hazard of recurrence ( Figure 2, Table 2) , the curves or hazard ratio also might be explained if older women were less likely to be treated with chemotherapy for a recurrence, i.e., they would be more likely to get hormonal therapy and either never get chemo or get it later in time.
Breast cancer can recur at any time throughout the patient's lifetime. A recently published overview by the Early Breast Cancer Trialists' Collaborative Group looked at 15-year breast cancer recurrence and survival rates, and although the hazard ratios for recurrence were highest during the first few years after diagnosis, there seemed to be a steady relapse rate through 15 years and beyond (30) . They found that for women with ER-positive breast cancer treated with tamoxifen for 5 years, the 15-year probability of death from breast cancer is more than 3 times as great as the 5-year probability. Their studies suggested that the majority of breast cancer recurrences occurred more than 5 years after diagnosis when patients were observed for more than 15 years. These findings have implications for long-term breast cancer surveillance (30) .
Our current study also showed that the annual HR of recurrence remained above zero to the end of the 10 years of study, also implying that we might boost patient benefit by continuing to monitor for recurrence beyond 5 or 10 years after breast cancer diagnosis in women.
With the consistently increasing number of new breast cancer cases each year and more women entering survivorship, it is worthwhile to reconsider the follow-up or surveillance schedules for women after primary treatment (31) (32) (33) . For example, we shall plan to utilize the current available data and develop a practical statistical model to offer a schedule that considers known adverse prognostic factors. Creating objective decisions derived from evidence or searching for a balance to shape the current follow-up schedules will improve the early detection of recurrence and consequently lead to individualized patient care in the future.
We acknowledge several limitations in our present study. First, inaccuracies in coding the SEER and Medicare data may have varied over time. Second, pathological reports have been read by different pathologists at different sites and there could be variations with site and time.
Third, our study included only women between 65 and 80 years of age, and therefore the results derived may not represent the broader U.S. population. Forth, the cancer recurrence information was captured by using Medicare data and therefore misreporting due to coding issues might happen. Our data also excluded 13% of women who were enrolled in HMOs or who were not fully covered by Medicare Parts A and B during the follow-up periods. Although the frequency distributions of cases between those included and excluded were very close in terms of tumor stage, grade, and hormone status, the distribution of age differed: women who were excluded from the study were younger than patients chosen for the study. SEER-Medicare data make it the optimal source to determine the relationship between the recurrence of breast cancer and the hazard function over time.
In summation, our results using 10 years of follow-up data yield pertinent information on trends for first cancer recurrence in women with breast cancer. Specifically, our results demonstrate that the annual HR of recurrence is not uniformly distributed over time but is dynamic and markedly determined by prognostic factors at diagnosis. Our results also show that recurrence was most likely to occur in the first 5 years of follow-up, which supports the current guidelines for an intensive follow-up schedule in this time period.
Our findings suggest that follow-up visits should be planned according to the times when the recurrence events are most likely to occur, as determined by known prognostic factors. Given our findings, researchers can begin to answer questions about the frequency of follow-up, the total duration of follow-up, and which tests are most appropriate for each patient during each follow-up visit. 
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